Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 10/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524114 | 0.93 | CTSL (0.56) | LMNACTSLCTSSCTSKCTSB | |
| SCHEMBL5529158 | 0.90 | CTSL (0.49) | LMNACTSLCTSSCTSKCTSB | |
| SCHEMBL5532170 | 0.90 | CTSB (0.53) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5527001 | 0.89 | ESRRG (0.51) | LMNACTSLCTSSCTSKCTSB | |
| SCHEMBL5529048 | 0.88 | CTSL (0.52) | LMNACTSLCTSSCTSKCTSB | |
| SCHEMBL5523613 | 0.88 | CTSL (0.46) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5522863 | 0.88 | CTSB (0.62) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5532200 | 0.86 | CTSS (0.61) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5525939 | 0.86 | CTSL (0.54) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5528253 | 0.86 | NPC1 (0.46) | LMNACTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | LMNA 1476/4885CTSL 10/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.